To participate in CPAs, pharmacists must be able to assess the health status of their patients, implement a pharmaceutical care plan, communicate with stakeholders and monitor patient progress. This also involves determining when it should intervene in a patient`s drug therapy.  Pharmacists may receive registration information from organizations approved by the Pharmacy Council.  Arizona`s CPAs apply to pharmacists and individual practitioners designated by law as “providers.” Providers include established doctors or nurses. The CPA must indicate the conditions of the disease, the medications, the conditions of notification of the supplier and the laboratory tests that the pharmacist can order. Pharmacists may monitor or modify a patient`s drug treatment in accordance with CPA, provided that the provider and pharmacist have a reciprocal patient-practitioner relationship with the patient.  Arkansan CPAs apply to individual pharmacists, practitioners admitted as “authorized practitioners to prescribe drugs” and patients. The specific disease stipulates that pharmacists administer, with indicated medications that the pharmacist can use are necessary. Pharmacists are required to document their interventions for discussion with the collaborative practitioner and must keep these records for at least 2 years after the date of registration.  Alaska`s CPAs may include several pharmacists and practitioners (for example. B a pharmacist who takes a CPA with a group of staff physicians, several pharmacists who contract a CPA with a physician, or several pharmacists who contract a CPA with several pharmacists), although a “primary prescriber” must be designated. The CPA must indicate the condition of the disease, the medications (or classes of medications) on which pharmacists are authorized to make decisions, and a procedure/protocol available for these decisions. Decisions must be reviewed at least every three months, at the same time as the agencies involved, and the protocols are only applicable for a maximum of two years.
 The Alaska CPAs allow pharmacists to monitor drug treatment on 12 AAFC 52.995, which involves conducting a full medical experiment, measuring vital signs and ordering/evaluating laboratory tests covered by CPA.   A pharmacist must meet one of the following criteria to be a cPP: In 2012, the AAFP submitted a position paper expressing support for CPAs, but highlighted the risk of fragmentation of supply when pharmacists were given fully autonomous prescription privileges.  Legal guidelines and requirements for the constitution of the CPA are defined on a state-based basis.  The federal government approved the CPAs in 1995.  Washington was the first state to pass laws allowing formal formation of CPAs. In 1979, Washington changed the practice of pharmaceutical requirements that provide for the formation of “collaborative drug therapy agreements.” [Citation required] Since February 2016, 48 states and Washington D.C have passed laws that allow the availability of CPAs.  The only two states that do not allow cpAs to be made available are Alabama and Delaware.  Alabama pharmacists hoped that a CPA law, House Bill 494, would be passed in 2015.  The bill was introduced by Alabama House Of Representatives Representative Ron Johnson, but died in committee.  As part of the Cooperation Practices Agreement, a CPC has a provision for controlled and uncontrolled substances.  Pharmacists can help physicians treat chronic diseases of street patients in different ways: CDTM is an extension of the traditional practice of pharmacists that allows for pharmacist-managed management of drug-related problems (DOP), with an emphasis on a collaborative and interdisciplinary approach to pharmaceutical practice in the health field.